|Chemical and physical data|
|Molar mass||446.555 g·mol−1|
|3D model (JSmol)|
Erdafitinib is a small molecule inhibitor of FGFR approved for treatment of cancer and marketed under the name Balversa. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival. Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.
In April 2019, erdafitinib was granted approval by the FDA for treatment of metastatic or locally advanced bladder cancer with an FGFR3 or FGFR2 alteration that has progressed beyond traditional platinum-based therapies, subject to a confirmatory trial.
- "Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer - Johnson & Johnson". www.jnj.com.
- "Erdafitinib - Janssen Pharmaceutica - AdisInsight". adisinsight.springer.com.
- "FDA approves first targeted therapy for metastatic bladder cancer". www.fda.gov. Retrieved 2019-05-13.